STAAR Surgical Company - Common Stock (NQ:STAA)

STAAR Surgical Co (NASDAQ:STAA) Stock Plummets on Q4 Revenue Miss ↗

March 03, 2026

Via Chartmill

STAAR Surgical (NASDAQ:STAA) Misses Q4 CY2025 Sales Expectations, Stock Drops 11.2%

March 03, 2026

STAAR Surgical Issues Shareholder Letter

March 03, 2026

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

March 03, 2026

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

February 25, 2026

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

February 23, 2026

FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

February 17, 2026

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

3 Low-Volatility Stocks We Find Risky

February 15, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

1 Cash-Heavy Stock on Our Watchlist and 2 We Brush Off

February 09, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even...

3 Cash-Burning Stocks with Open Questions

February 04, 2026

Shares of medical lens company STAAR Surgical (NASDAQ:STAA) fell 3.5% in the afternoon session after the company announced a leadership transition, appointing interim co-CEOs following the recent...

Topics Bankruptcy

Why STAAR Surgical (STAA) Stock Is Trading Lower Today

February 02, 2026

STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

February 02, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and...

3 Healthcare Stocks Walking a Fine Line

January 18, 2026

STAAR Surgical’s 23.7% return over the past six months has outpaced the S&P 500 by 13.1%, and its stock price has climbed to $21.14 per share. This was partly due to its solid quarterly results, and...

Topics Stocks

STAAR Surgical (STAA): Buy, Sell, or Hold Post Q3 Earnings?

January 15, 2026

Topics Stocks

STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

January 15, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

3 Stocks Under $50 That Fall Short

January 11, 2026

Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon

Topics Economy

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

January 06, 2026

Via Chartmill

January 06, 2026

From Broadwood Partners, L.P.

STAAR Surgical Announces Preliminary Results of Special Meeting of Stockholders

January 06, 2026

STAAR’s results show a story about timing, cash discipline, and what happens when reported growth finally lines up with underlying demand.

New $17 Million Bet on STAAR Surgical Comes as Sales Jump 7% and Margins Hit 82% ↗

December 30, 2025

Via The Motley Fool

Topics Regulatory Compliance

3 Low-Volatility Stocks We Keep Off Our Radar

December 28, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

What a $22 Million Bet on STAAR Surgical Signals After Third-Quarter Earnings and a 15% Market Lag ↗

December 23, 2025

The stock is roughly flat this past year, but the fundamentals quietly moved in the right direction, and that disconnect likely caught this fund’s attention.

Via The Motley Fool

Topics Regulatory Compliance

3 Cash-Heavy Stocks We Keep Off Our Radar

December 21, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon

December 19, 2025

From Broadwood Partners, L.P.

Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders

December 19, 2025

Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails

December 17, 2025

From Broadwood Partners, L.P.

STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value

December 17, 2025

Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory

December 16, 2025

From Yunqi Capital Limited

Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction

December 16, 2025